VJ - Antifungals II Flashcards

1
Q

What are some mechanisms of antifungal resistance? (2)

A
  • Mutation in glucan synthesis target site
  • Fungal cells can send signals to inform neighboring cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the mechanism of resistance to Echinocandins? (2)

A
  • Echinocandins inhibit 1,3-beta-glucan synthase, disrupting cell wall synthesis.
  • Mutations in FKS1 reduce drug binding, leading to increased resistance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the key stress response mechanisms in fungi under echinocandin exposure? (2)

A
  • HSP90 and Calcineurin aid in stress tolerance.
  • RAS and Unfolded Protein Response (UPR) maintain cell wall integrity.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How do fungi exhibit resistance to Polyenes? (2)

A
  • Altered cell membrane permeability due to reduced ergosterol production.
  • Some fungi may use alternative sterols to reduce polyene efficacy.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are 2 response mechanisms to polyene-induced membrane stress?

A
  • Some fungi upregulate ERG5, ERG6, and ERG25 to increase ergosterol synthesis, enhancing tolerance to polyenes.
  • HSP90 and Cellular Stress Regulators activate pathways that help fungi survive membrane stress caused by polyenes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are 3 effects to polyene-induced membrane stress?

A

Polyene-ergosterol complexes

  • disrupt protein gradients
  • cause osmotic lysis
  • disturb cellular ion balance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the resistance mechanisms to Azoles? (4)

A

1) Reduced Drug Binding

  • Mutations in CYP51A/ERG11 reduce azole binding to the target enzyme (e.g., TR₃₄/L98H mutation).

2) Overexpression of Drug Target

  • Increased expression of CYP51A raises the target enzyme levels, decreasing drug efficacy.

3) Increased Drug Efflux

  • Overexpression of efflux pumps reduces intracellular drug concentration.

4) Hypermutation and Heteroresistance

  • MSH2 mutations lead to hypermutation, contributing to genetic diversity and resistance.
  • Heteroresistance occurs due to variability in resistance within a fungal population.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How does aneuploidy contribute to antifungal resistance?

A

Extra copies of chromosomes increase gene dosage, enhancing resistance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is involved in the prodrug activation pathway of Flucytosine? (2)

A
  • Flucytosine is a prodrug converted to active metabolites (5-fluorouracil and 5-fluorodeoxyuridine monophosphate) that inhibit DNA/RNA synthesis.
  • Mutations in enzymes FCY1, FCA2, and FUR1 block this conversion, preventing the inhibition of DNA/RNA synthesis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are two mechanisms of resistance to Flucytosine?

A

Reduced Drug Uptake:

  • Mutations reduce uptake via cytosine permease, lowering intracellular flucytosine levels.

Reduced Affinity for Active Metabolites:

  • Point mutations decrease affinity for 5-fluorouracil (5-FU) and 5-fluorodeoxyuridine monophosphate (5-FUMP), diminishing drug action.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does hypermutation contribute to antifungal resistance?

A

Hypermutation increases genetic variation, which contributes to the development of resistance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the genetic approaches for identifying new antifungal targets? (2)

A
  • Identify the minimal genome by focusing on essential genes to prevent resistance and non-conserved genes for selective targeting.
  • Use knockout screening to determine gene essentiality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What resources are utilized in database comparisons for identifying new antifungal targets? (3)

A
  • Database of Essential Genes (DEG)
  • Online Gene Essentiality (OGEE)
  • Essential Genes on Genomic Scale (EGGA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are some target examples for antifungal therapies? (2)

A

Inositol Phosphorylceramide Synthase (AUR1)

  • Involved in sphingolipid synthesis, a potential antifungal target.

Cryptococcus Trehalose-6-Phosphate Synthase (TPS1) and Trehalose-6-Phosphate Phosphatase (TPS2)

  • Regulate glycolysis and are selective targets as they are not found in mammals
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are Triterpenoids in the context of antifungal agents?

A

Triterpenoids represent the first new class of antifungals in approximately 20 years and were approved for use in the US in June 2021

17
Q

How do Triterpenoids work as antifungal agents?

A

Target the same enzyme as echinocandins (glucan-synthase Fks1p) but bind at a different site, potentially reducing cross-resistance.

18
Q

What are the advantages of using Triterpenoids? (2)

A
  • Key advantage includes oral administration, improving patient compliance and treatment accessibility.
  • Effective against resistant Candida strains, including C. auris.
19
Q

What are the concerns associated with Triterpenoids?

A

The emergence of resistance remains a question, highlighting the need for ongoing surveillance and research

20
Q
A
20
Q

What are some potential strategies for antifungal treatment development? (4)

A
  • Re-purpose other drugs, such as anti-cancer drugs.
  • Target pathogen-specific species to enhance treatment effectiveness
  • Develop vaccines to provide preventative measures against fungal infections
  • Create antibodies to enhance the immune response against specific fungal pathogens.